Background/Objectives:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with the Asia-Pacific (APAC) region bearing a disproportionate burden. This paper examines HCC challenges within seven APAC health systems, identifies key barriers at each stage of the patient journey, and proposes tailored, actionable solutions. To effectively address HCC challenges, a stepwise approach should prioritise high-impact solutions, focusing on prevention, early diagnosis, and expanding surveillance to maximise health outcomes and economic benefits, while tailoring strategies to each health system’s unique resources and constraints.Methods:A mixed-methods approach was used, including expert consultations from the 2024 HCC APAC Policy Forum, a literature review, and a review of Japan’s HCC management model. Data were collected through workshops and stakeholder feedback from healthcare professionals, policymakers, researchers and patient advocates across Australia, India, Malaysia, South Korea, Taiwan, Thailand, and Vietnam.Results:Key findings include significant disparities in HCC awareness, prevention, early detection, diagnosis, and access to treatment. Common challenges across APAC include limited public awareness, suboptimal surveillance infrastructure, and financial barriers to care. The integration of novel biomarkers and advanced surveillance modalities were identified as crucial priorities for improving early detection. Japan’s multi-faceted approach to HCC management serves as a successful model for the region.Conclusions:A customised and targeted approach is essential for reducing the HCC burden across APAC. The proposed recommendations, tailored to each health system’s needs, can significantly improve patient outcomes and reduce healthcare costs. Effective collaboration among stakeholders is necessary to drive these changes.
背景/目的：肝细胞癌（HCC）是癌症相关死亡的主要原因，亚太地区承受着尤为沉重的疾病负担。本文审视了亚太地区七个医疗体系内HCC面临的挑战，识别了患者诊疗路径各阶段的关键障碍，并提出了针对性、可操作的解决方案。为有效应对HCC挑战，应采取分步实施策略，优先推进高影响力措施，聚焦预防、早期诊断及扩大筛查范围，以最大化健康效益与经济收益，同时根据各医疗体系独特的资源与限制条件定制策略。 方法：本研究采用混合方法，包括2024年亚太HCC政策论坛专家咨询、文献综述及日本HCC管理模式分析。数据通过研讨会及来自澳大利亚、印度、马来西亚、韩国、台湾、泰国和越南的医疗专业人员、政策制定者、研究人员及患者倡导者的利益相关方反馈收集。 结果：主要发现包括HCC认知、预防、早期发现、诊断及治疗可及性方面存在显著差异。亚太地区面临的共同挑战包括公众认知不足、筛查基础设施不完善以及医疗费用障碍。整合新型生物标志物与先进监测模式被确定为改善早期检测的关键优先事项。日本多层次的HCC管理模式为该地区提供了成功范例。 结论：定制化、有针对性的策略对减轻亚太地区HCC负担至关重要。结合各医疗体系需求提出的建议可显著改善患者预后并降低医疗成本。利益相关方间的有效协作是推动这些变革的必要条件。
Roadmap for HCC Surveillance and Management in the Asia Pacific
肿瘤(癌症)患者之家